Check-Cap Stock (NASDAQ:CHEK)


ForecastOwnershipChart

Previous Close

$1.54

52W Range

$0.56 - $3.13

50D Avg

$1.51

200D Avg

$1.00

Market Cap

$9.48M

Avg Vol (3M)

$2.95M

Beta

0.69

Div Yield

-

CHEK Company Profile


Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

85

IPO Date

Mar 04, 2015

Website

CHEK Performance


Peer Comparison


TickerCompany
SINTSintx Technologies, Inc.
LFWDLifeward Ltd.
MRKRMarker Therapeutics, Inc.
RNAZTransCode Therapeutics, Inc.
DWTXDogwood Therapeutics, Inc.
CODXCo-Diagnostics, Inc.
EVGNEvogene Ltd.
ABPAbpro Corporation
FLGCFlora Growth Corp.
TRIBTrinity Biotech plc